Hwang, J. D., Cunha, M. T., Russell, M., Pardo, G., Alsharif, H., Rind, F., Gogineni, E., Zhu, S., Konieczkowski, D. J., Grecula, J. C., Mitchell, D. L., Miller, L., Haring, C., Seim, N., VanKoevering, K., Kang, S., Rocco, J. W., Blakaj, D., Bhateja, P., Bonomi, M. R. (2026). Second-line cetuximab plus immune checkpoint inhibitor (ICI) versus cetuximab plus carboplatin and paclitaxel following ICI-containing regimen in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6046